MTNB Stock Chart

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on the development of MAT9001, a candidate for the treatment of cardiovascular and metabolic conditions. The medication is an omega-3 fatty acid-based composition, comprised of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DPA), designed to overcome the shortcomings seen from other agents in the omega-3 class. In addition, the company develops MAT2203, a formulation of Amphotericin B designed to treat invasive fungal infections.